| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-09 00:10:31 UTC |
|---|
| Updated at | 2022-09-09 00:10:31 UTC |
|---|
| NP-MRD ID | NP0276180 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | 4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-{[(1r)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}phenol |
|---|
| Description | Liensinine belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached. 4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-{[(1r)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}phenol is found in Nelumbo nucifera. 4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-{[(1r)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}phenol was first documented in 2019 (PMID: 31738137). Based on a literature review a significant number of articles have been published on Liensinine (PMID: 33964997) (PMID: 33166629) (PMID: 36059960) (PMID: 35762411) (PMID: 35813859) (PMID: 35116094). |
|---|
| Structure | COC1=CC2=C(C=C1OC)[C@@H](CC1=CC=C(O)C(OC3=CC4=C(CCN(C)[C@@H]4CC4=CC=C(O)C=C4)C=C3OC)=C1)N(C)CC2 InChI=1S/C37H42N2O6/c1-38-14-13-26-20-35(43-4)37(22-29(26)30(38)16-23-6-9-27(40)10-7-23)45-33-18-24(8-11-32(33)41)17-31-28-21-36(44-5)34(42-3)19-25(28)12-15-39(31)2/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3/t30-,31-/m1/s1 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C37H42N2O6 |
|---|
| Average Mass | 610.7510 Da |
|---|
| Monoisotopic Mass | 610.30429 Da |
|---|
| IUPAC Name | 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-2-{[(1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}phenol |
|---|
| Traditional Name | 4-{[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl}-2-{[(1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy}phenol |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | COC1=CC2=C(C=C1OC)[C@@H](CC1=CC=C(O)C(OC3=CC4=C(CCN(C)[C@@H]4CC4=CC=C(O)C=C4)C=C3OC)=C1)N(C)CC2 |
|---|
| InChI Identifier | InChI=1S/C37H42N2O6/c1-38-14-13-26-20-35(43-4)37(22-29(26)30(38)16-23-6-9-27(40)10-7-23)45-33-18-24(8-11-32(33)41)17-31-28-21-36(44-5)34(42-3)19-25(28)12-15-39(31)2/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3/t30-,31-/m1/s1 |
|---|
| InChI Key | XCUCMLUTCAKSOZ-FIRIVFDPSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Isoquinolines and derivatives |
|---|
| Sub Class | Benzylisoquinolines |
|---|
| Direct Parent | Benzylisoquinolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzylisoquinoline
- Diaryl ether
- Tetrahydroisoquinoline
- Phenoxy compound
- Anisole
- Phenol ether
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Aralkylamine
- Phenol
- Monocyclic benzene moiety
- Benzenoid
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Liu CM, Wu Z, Pan B, An L, Zhu C, Zhou J, Jiang Y: The antiandrogenic effect of neferine, liensinine, and isoliensinine by inhibiting 5-alpha-reductase and androgen receptor expression via PI3K/AKT signaling pathway in prostate cancer. Pharmazie. 2021 May 1;76(5):225-231. doi: 10.1691/ph.2021.1301. [PubMed:33964997 ]
- Zhang H, Wang X, Guo Y, Liu X, Zhao X, Teka T, Lv C, Han L, Huang Y, Pan G: Thirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: Botany, traditional uses, phytochemistry, pharmacokinetic and toxicity studies. J Ethnopharmacol. 2021 Mar 25;268:113566. doi: 10.1016/j.jep.2020.113566. Epub 2020 Nov 7. [PubMed:33166629 ]
- Manogaran P, Beeraka NM, Padma VV: The Cytoprotective and Anti-cancer Potential of Bisbenzylisoquinoline Alkaloids from Nelumbo nucifera. Curr Top Med Chem. 2019;19(32):2940-2957. doi: 10.2174/1568026619666191116160908. [PubMed:31738137 ]
- Xiao X, Luo F, Fu M, Jiang Y, Liu S, Liu B: Evaluating the therapeutic role of selected active compounds in Plumula Nelumbinis on pulmonary hypertension via network pharmacology and experimental analysis. Front Pharmacol. 2022 Aug 17;13:977921. doi: 10.3389/fphar.2022.977921. eCollection 2022. [PubMed:36059960 ]
- Meng XL, Liu SY, Xue JS, Gou JM, Wang D, Liu HS, Chen CL, Xu CB: Protective effects of Liensinine, Isoliensinine, and Neferine on PC12 cells injured by amyloid-beta. J Food Biochem. 2022 Oct;46(10):e14303. doi: 10.1111/jfbc.14303. Epub 2022 Jun 28. [PubMed:35762411 ]
- Chang M, Ding S, Dong X, Shang X, Li Y, Xie L, Song X, Song X: Liensinine Inhibits Cell Growth and Blocks Autophagic Flux in Nonsmall-Cell Lung Cancer. J Oncol. 2022 Jul 1;2022:1533779. doi: 10.1155/2022/1533779. eCollection 2022. [PubMed:35813859 ]
- Jia F, Liu Y, Dou X, Du C, Mao T, Liu X: Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. Oxid Med Cell Longev. 2022 Jan 25;2022:8245614. doi: 10.1155/2022/8245614. eCollection 2022. [PubMed:35116094 ]
- Liang L, Ye S, Jiang R, Zhou X, Zhou J, Meng S: Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. Int Immunopharmacol. 2022 Mar;104:108306. doi: 10.1016/j.intimp.2021.108306. Epub 2022 Jan 6. [PubMed:34999396 ]
- Shi MZ, Yu YL, Zhu SC, Gu YX, Yue ZX, Yan TC, Zheng H, Cao J: Boron nitride nanosheet-assisted matrix solid-phase dispersion microextraction of alkaloids from lotus plumule by high-performance liquid chromatography coupled with ultraviolet detection and ion mobility quadrupole time-of-flight mass spectrometry. Electrophoresis. 2022 Feb;43(4):581-589. doi: 10.1002/elps.202100286. Epub 2021 Nov 21. [PubMed:34755364 ]
- Wei F, Gou X, Xu X, Wang S, Bao T: Sensitive Quantification of Liensinine Alkaloid Using a HPLC-MS/MS Method and Its Application in Microvolume Rat Plasma. J Anal Methods Chem. 2021 Feb 26;2021:6629579. doi: 10.1155/2021/6629579. eCollection 2021. [PubMed:33728092 ]
- Liang X, Wang S, Wang L, Ceylan AF, Ren J, Zhang Y: Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission. Pharmacol Res. 2020 Jul;157:104846. doi: 10.1016/j.phrs.2020.104846. Epub 2020 Apr 25. [PubMed:32339784 ]
- Yang JH, Yu K, Si XK, Li S, Cao YJ, Li W, Zhang JX: Liensinine inhibited gastric cancer cell growth through ROS generation and the PI3K/AKT pathway. J Cancer. 2019 Oct 19;10(25):6431-6438. doi: 10.7150/jca.32691. eCollection 2019. [PubMed:31772676 ]
- Wang T, Streeter H, Wang X, Purnama U, Lyu M, Carr C, Ma YL: A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning. Front Pharmacol. 2019 Sep 25;10:1138. doi: 10.3389/fphar.2019.01138. eCollection 2019. [PubMed:31607935 ]
- Xie S, Li Y, Teng W, Du M, Li Y, Sun B: Liensinine Inhibits Beige Adipocytes Recovering to white Adipocytes through Blocking Mitophagy Flux In Vitro and In Vivo. Nutrients. 2019 Jul 18;11(7):1640. doi: 10.3390/nu11071640. [PubMed:31323747 ]
- LOTUS database [Link]
|
|---|